Skip to main content

Table 3 Clinical factors associated with SII

From: Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

Variables

Low SII (n = 29)

High SII (n = 29)

P value

Age

  

0.599

  < 60

15 (51.7)

13(44.8)

 

  ≥ 60

14(48.3)

16(55.2)

 

Sex

  

0.640

 Male

26(89.7)

27(93.1)

 

 Female

3(10.3)

2(6.9)

 

Child Pugh score

  

0.401

 A5

18(62.1)

21(72.4)

 

 A6

11(37.9)

8(27.6)

 

ALBI grade

  

1.000

 1

13(44.8)

13(44.8)

 

 2

16(55.2)

16(55.2)

 

AFP (ng/mL)

  

0.597

  < 400

14(48.3)

12(41.4)

 

  ≥ 400

15(51.7)

17(58.6)

 

PIVKA-II (mAU/mL)

  

0.240

  < 1000

10(34.5)

6(20.7)

 

  ≥ 1000

19(65.5)

23(79.3)

 

NLR

  

0.000

  < 2.4

23(79.3)

5(17.2)

 

  ≥ 2.4

6(20.7)

24(82.8)

 

PLR

  

0.000

  < 108

12(79.3)

6(20.7)

 

  ≥ 108

6(20.7)

23(79.3)

 

BCLC stage

  

0.036

 B

11(37.9)

4(13.8)

 

 C

18(62.1)

25(86.2)

 

Vascular invasion

  

1.000

 No

20(69.0)

20(69.0)

 

 Yes

9(31.0)

9(31.0)

 

Extrahepatic metastases

  

0.104

 No

14(48.3)

8(37.6)

 

 Yes

15(51.7)

21(72.4)

 
  1. Values are presented as number (%) of patients
  2. AFP alpha-fetoprotein, ALBI albumin–bilirubin, BCLC Barcelona Clinic Liver Cancer, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PIVKA protein induced by vitamin K absence or antagonist, SII systemic immune-inflammation index